Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

针对精神分裂症，目前所有获批上市的抗精神病药均为突触后多巴胺D2受体拮抗剂或部分激动剂，尤其是前者。这些药物为成千上万的患者带来了确切的获益，但也存在诸多局限性，如与D2受体阻断相关的不良反应，代谢副作用，针对某些症状维度疗效有限，以及部分患者治疗反 ...

“KarXT是继20世纪50年代初第一代抗精神病药氯丙嗪诞生后，首款采用全新作用机制的抗精神病药物，两者相差70年左右。KarXT的获批有望为精神分裂症患者带来更多治疗选择。”9月27日，北京回龙观医院精神科主任医师陈松告诉人民日报健康客户端记者。

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...